Adrenomed Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $774K

  • Investors
  • 10

Adrenomed General Information

Description

Developer of clinical-stage pharmaceutical products designed to improve vascular integrity. The company's products use biomarker-guided monoclonal antibody therapies that offer a causative, safe treatment for acute circulatory failure, enabling doctors to reduce vascular leakage, stabilize the circulation, and lower mortality.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Neuendorfstraße 15A
  • 16761 Hennigsdorf
  • Germany
+49 03302
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Neuendorfstraße 15A
  • 16761 Hennigsdorf
  • Germany
+49 03302

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adrenomed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 01-May-2025 $774K Completed Clinical Trials - Phase 2
5. Later Stage VC 05-Jul-2022 Completed Clinical Trials - Phase 2
4. Later Stage VC 30-Aug-2021 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series E) 23-Mar-2021 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series D) 17-Jun-2020 $30.2M $30.2M Completed Clinical Trials - Phase 2
1. Later Stage VC 01-Jan-2014 Completed Clinical Trials - Phase 2
To view Adrenomed’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Adrenomed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of clinical-stage pharmaceutical products designed to improve vascular integrity. The company's products use b
Drug Discovery
Hennigsdorf, Germany
18 As of 2026

Antwerp, Belgium
 

Schlieren, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adrenomed Competitors (57)

One of Adrenomed’s 57 competitors is Agomab Therapeutics, a Formerly VC-backed company based in Antwerp, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agomab Therapeutics Formerly VC-backed Antwerp, Belgium
Virometix Venture Capital-Backed Schlieren, Switzerland
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
Abivax Formerly PE-Backed Paris, France
You’re viewing 5 of 57 competitors. Get the full list »

Adrenomed Patents

Adrenomed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4345109-A1 Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease Inactive 30-Sep-2022
AU-2023313376-A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock Pending 29-Jul-2022
EP-4562035-A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock Pending 29-Jul-2022
US-20260167706-A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock Pending 29-Jul-2022
WO-2024023369-A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock Inactive 29-Jul-2022 C07K16/22
To view Adrenomed’s complete patent history, request access »

Adrenomed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adrenomed Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
VU Venture Partners Venture Capital Minority
HINKEL & Cie Corporation Minority
Deutsche Biotech Innovativ Corporation Minority
HBM Healthcare Investments Venture Capital Minority
HBM Partners Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Adrenomed FAQs

  • When was Adrenomed founded?

    Adrenomed was founded in 2009.

  • Where is Adrenomed headquartered?

    Adrenomed is headquartered in Hennigsdorf, Germany.

  • What is the size of Adrenomed?

    Adrenomed has 18 total employees.

  • What industry is Adrenomed in?

    Adrenomed’s primary industry is Drug Discovery.

  • Is Adrenomed a private or public company?

    Adrenomed is a Private company.

  • What is Adrenomed’s current revenue?

    The current revenue for Adrenomed is .

  • How much funding has Adrenomed raised over time?

    Adrenomed has raised $61.3M.

  • Who are Adrenomed’s investors?

    VU Venture Partners, HINKEL & Cie, Deutsche Biotech Innovativ, HBM Healthcare Investments, and HBM Partners are 5 of 10 investors who have invested in Adrenomed.

  • Who are Adrenomed’s competitors?

    Agomab Therapeutics, Virometix, Inovio Pharmaceuticals, NGM Biopharmaceuticals, and Abivax are some of the 57 competitors of Adrenomed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process